MI-136

Catalog No.C12971 Batch:C1297103

Product Datasheet

Technical Data

Formula	$C_{23}H_{21}F_3N_6S$					
Molecular Weight	470.51	**CAS No.**	1628316-74-4			
Solubility (25°C)*	In vitro	DMSO	94 mg/mL (199.78 mM)			
		Ethanol	94 mg/mL (199.78 mM)			
		Water	Insoluble			
	In vivo (Add solvents to the product individually and in order)	Oral Administration	Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Capsid Bio tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped at 2-8°C for storage purposes.)

Preparing Stock Solutions

Biological Activity

Description	MI-136 can specifically inhibit the **menin-MLL** interaction. It inhibits DHT-induced expression of **androgen receptor (AR)** target genes.
Targets	Menin-MLL interaction [1]
In vitro	MI-136, a variant of a previously described inhibitor that can specifically inhibit the menin-MLL interaction. AR positive cell lines such as VCaP, LNCaP and 22RV1 are sensitive to this compound. Treatment with this chemical also inhibits the expression of genes that are bound to ASH2L after AR stimulation. Treatment with this compound induces apoptosis of VCaP cells as evidenced by PARP (cPARP) cleavage and blocks DHT-induced cell proliferation in AR-dependent cell lines (LNCaP and VCaP). The effect of this inhibitor on cell proliferation is similar to MDV-3100, a second-generation FDA-approved anti-androgen for patients with refractory prostate cancer[1].
In vivo	Treatment of VCaP tumor-bearing mice with MI-136 (40mg/kg) leads to a modest but significant reduction in tumor volume with no effect on mouse body weight[1].

Protocol (from reference)

Cell Assay:[1]

- **Cell lines**
  VCaP cells
- **Concentrations**
  5 μM
- **Incubation Time**
  48 h
- **Method**
  To assess the effect of MI-136 on AR signaling, VCaP cells are treated with DMSO or 5 μM of this compound for 48 hours. Cells are serum starved by replacing the media with DMEM containing 5% charcoal-striped serum and this chemical for 48 hrs. Cells are then stimulated with 10nM DHT for 12 hrs and RNA is isolated and processed for expression microarrays.

Animal Study:[1]

- **Animal Models**
  VCaP tumor-bearing mice（VCaP xenografts）
- **Dosages**
  40 mg/kg
- **Administration**
  i.p.

References

https://pubmed.ncbi.nlm.nih.gov/25822367/

RETURN POLICY

Capsid Bio's Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING & STORAGE

Capsid Bio products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Capsid Bio Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Capsid Bio products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

EU Headquarters
Gajeva ulica 28, HR-10000 Zagreb, Croatia

US Headquarters
12222 Merit Dr STE 130 Dallas, Texas, 75251

UK Headquarters
121 ABILITY HOUSE, BROOKER ROAD, EN9 1JH, ESSEX

Orders: Sales@capsidbio.com
Enquiries: info@capsidbio.com
www.capsidbio.com